long intergenic non-protein coding RNA 1517Genealiases: []
Q-omics provides the consensus-scored LINC01517 profile across patient tissues and cancer cell-line models. LINC01517 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01517 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LINC01517 RNA expression shows 6,874 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where LINC01517 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01517 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01517 survival associations across molecular data types. LINC01517 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01517 RNA expression–survival associations across cancer types. High LINC01517 expression shows unfavorable associations in SKCM, CESC, BRCA and ACC, but favorable associations in OV and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01517 RNA expression.
This table summarizes LINC01517 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01517. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01517 shows lower tumor expression in KIRC, KIRP, KICH and COAD and higher tumor expression in CHOL and LIHC. The KIRC box plot shows higher LINC01517 RNA expression in normal versus tumor tissue (log2 FC = −0.254, t-test p < 0.001).
This table shows molecular features associated with LINC01517 in patient tissues and cancer cell lines. In patient samples, LINC01517 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
